Agios Pharmaceuticals (AGIO) Given Coverage Optimism Score of 0.12
News stories about Agios Pharmaceuticals (NASDAQ:AGIO) have trended somewhat positive on Friday, Accern reports. Accern identifies positive and negative press coverage by reviewing more than 20 million blog and news sources. Accern ranks coverage of public companies on a scale of -1 to 1, with scores closest to one being the most favorable. Agios Pharmaceuticals earned a news sentiment score of 0.12 on Accern’s scale. Accern also assigned news headlines about the biopharmaceutical company an impact score of 44.5000888551237 out of 100, meaning that recent press coverage is somewhat unlikely to have an impact on the stock’s share price in the near term.
These are some of the headlines that may have impacted Accern Sentiment Analysis’s scoring:
- Agios Pharmaceuticals, Inc. (AGIO) Director Sells $227,862.06 in Stock (americanbankingnews.com)
- Agios Pharmaceuticals, Inc. (AGIO) Insider Sells $130,455.34 in Stock (americanbankingnews.com)
- Agios Pharma (AGIO) Names Jacqualyn Fouse Ph.D. to Board (streetinsider.com)
- IBD Rating Upgrades: Agios Pharmaceuticals Flashes Improved Relative Price Strength (finance.yahoo.com)
- Cann Reaffirms Buy Rating for Agios Pharmaceuticals (AGIO) (americanbankingnews.com)
AGIO has been the topic of several recent research reports. Credit Suisse Group increased their price objective on shares of Agios Pharmaceuticals from $61.00 to $66.00 and gave the stock an “outperform” rating in a research note on Thursday, November 2nd. ValuEngine upgraded shares of Agios Pharmaceuticals from a “sell” rating to a “hold” rating in a research note on Friday, September 1st. Cann reiterated a “buy” rating on shares of Agios Pharmaceuticals in a research note on Tuesday. Needham & Company LLC raised their target price on shares of Agios Pharmaceuticals from $54.00 to $72.00 and gave the stock a “buy” rating in a research note on Thursday, August 10th. Finally, SunTrust Banks restated a “buy” rating and set a $80.00 target price on shares of Agios Pharmaceuticals in a research note on Wednesday, October 4th. Three analysts have rated the stock with a hold rating and eleven have issued a buy rating to the company’s stock. Agios Pharmaceuticals currently has an average rating of “Buy” and a consensus price target of $75.70.
Agios Pharmaceuticals (AGIO) traded up $0.14 during mid-day trading on Friday, hitting $60.97. 443,590 shares of the company were exchanged, compared to its average volume of 510,968. Agios Pharmaceuticals has a 1 year low of $39.24 and a 1 year high of $72.73.
Agios Pharmaceuticals (NASDAQ:AGIO) last issued its quarterly earnings results on Wednesday, November 1st. The biopharmaceutical company reported ($1.59) earnings per share (EPS) for the quarter, topping analysts’ consensus estimates of ($1.78) by $0.19. The company had revenue of $11.35 million during the quarter, compared to the consensus estimate of $10.85 million. Agios Pharmaceuticals had a negative return on equity of 69.64% and a negative net margin of 506.39%. Agios Pharmaceuticals’s revenue was up 26.4% on a year-over-year basis. During the same period last year, the company earned ($1.63) earnings per share. research analysts predict that Agios Pharmaceuticals will post -6.59 EPS for the current year.
In other news, CEO David P. Schenkein sold 35,000 shares of Agios Pharmaceuticals stock in a transaction on Monday, September 18th. The stock was sold at an average price of $67.12, for a total transaction of $2,349,200.00. Following the completion of the sale, the chief executive officer now directly owns 35,000 shares in the company, valued at $2,349,200. The transaction was disclosed in a filing with the SEC, which can be accessed through the SEC website. Also, Director Lewis Clayton Jr. Cantley sold 3,838 shares of Agios Pharmaceuticals stock in a transaction on Thursday, December 7th. The stock was sold at an average price of $59.37, for a total value of $227,862.06. Following the sale, the director now owns 80,851 shares of the company’s stock, valued at $4,800,123.87. The disclosure for this sale can be found here. Over the last 90 days, insiders sold 182,746 shares of company stock valued at $12,385,226. 5.43% of the stock is owned by corporate insiders.
About Agios Pharmaceuticals
Agios Pharmaceuticals, Inc is a clinical-stage biopharmaceutical company. The Company’s therapeutic areas of focus are cancer and rare genetic metabolic disorders, which are a group of over 600 rare genetic diseases caused by mutations, or defects, of single metabolic genes. The Company’s cancer product candidates are enasidenib and ivosidenib (AG-120), which target mutated isocitrate dehydrogenase 2 (IDH2) and isocitrate dehydrogenase 1 (IDH1), respectively, and AG-881, which targets both mutated IDH1 and mutated IDH2.
Receive News & Ratings for Agios Pharmaceuticals Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Agios Pharmaceuticals Inc. and related companies with Analyst Ratings Network's FREE daily email newsletter.